Skip to main content

Prof. Dr. Tobias Bald

Member, Steering-Committee Member

Institute of Experimental Oncology

Medical Faculty, University of Bonn University Hospital of Bonn Venusberg-Campus 1 53127 Bonn

+49 228 28751192


Our mission is to improve the treatment and prolong the survival of cancer patients. Using preclinical cancer models and patient-derived material we aim to decipher the complex interactions between immune cells and cancer cells to identify novel druggable targets. Our current research focuses on understanding the importance of activating receptors in anti-cancer immune responses.

Tobias Bald

Recent publications

  • On-treatment Modified Glasgow Prognostic Score Provides Predictive Information Complementary to Radiological Staging in Metastatic Urothelial Carcinoma on Immunotherapy.

    European urology oncology

    Authors: Jonas Saal, Viktor Grünwald, Tobias Bald, Manuel Ritter, Peter Brossart, Yoshihiko Tomita, Arndt Hartmann, Michael Hölzel, Markus Eckstein, Niklas Klümper

    View this publication
  • Pretreatment albumin is a prognostic and predictive biomarker for response to atezolizumab across solid tumors.

    Clinical & translational immunology

    Authors: Jonas Saal, Jörg Ellinger, Manuel Ritter, Peter Brossart, Michael Hölzel, Niklas Klümper, Tobias Bald

    View this publication
  • Integrating On-Treatment Modified Glasgow Prognostic Score and Imaging to Predict Response and Outcomes in Metastatic Renal Cell Carcinoma.

    JAMA oncology

    Authors: Jonas Saal, Tobias Bald, Markus Eckstein, Damian J Ralser, Manuel Ritter, Peter Brossart, Viktor Grünwald, Michael Hölzel, Jörg Ellinger, Niklas Klümper

    View this publication